TREATMENT OF NEUROPATHY WITH IGF-1-ENCODING DNA CONSTRUCTS AND HGF-ENCODING DNA CONSTRUCTS
The present invention relates to a method of treating neuropathy by administering DNA constructs, encoding a human IGF-1 isoform and a human HGF isoform. Further provided herein are various DNA constructs and pharmaceutical compositions including the DNA constructs that can be used for the combination therapy. The present invention provides a safe and effective way of treating neuropathic patients.
1 . A method of treating neuropathy, comprising the steps of:
administering to a subject having neuropathy a therapeutically effective amount of an IGF-1-encoding DNA construct comprising a polynucleotide of SEQ ID NO: 10; and
administering to the subject a therapeutically effective amount of an HGF-encoding DNA construct comprising a polynucleotide of SEQ ID NO: 13.
2 - 20 . (canceled)
21 . The method of claim 1 , wherein the IGF-1-encoding DNA construct and the HGF-encoding DNA construct are administered in an amount sufficient to reduce pain in the subject.
22 . The method of claim 1 , wherein the subject has diabetic neuropathy.
23 . The method of claim 1 , wherein the IGF-1-encoding DNA construct and the HGF-encoding DNA construct are administered by a plurality of intramuscular injections.
24 - 29 . (canceled)
30 . The method of claim 1 , wherein the IGF-1-encoding DNA construct and the HGF-encoding DNA construct are co-administered.
31 . The method of claim 30 , wherein the IGF-1-encoding DNA construct and the HGF-encoding DNA construct are co-administered by an intramuscular injection.
32 . The method of claim 1 , wherein the step of administering the IGF-1-encoding DNA construct and the step of administering the HGF-encoding DNA construct are performed separately.
33 . The method of claim 32 , wherein the step of administering the IGF-1-encoding DNA construct and the step of administering the HGF-encoding DNA construct are performed at least three weeks apart.
34 - 37 . (canceled)
38 . A pharmaceutical composition comprising:
an IGF-1-encoding DNA construct comprising a polynucleotide of SEQ ID NO: 10;
an HGF-encoding DNA construct comprising a polynucleotide of SEQ ID NO: 13, and
a pharmaceutically acceptable excipient.
39 - 45 . (canceled)
46 . The pharmaceutical composition of claim 38 , wherein the IGF-1-encoding DNA construct further comprises a plasmid vector.
47 . The pharmaceutical composition of claim 46 , wherein the plasmid vector is pCK.
48 . The pharmaceutical composition of claim 47 , wherein the IGF-1-encoding DNA construct is pCK-IGF-1X10.
49 . The pharmaceutical composition of claim 46 , wherein the plasmid vector is pTx.
50 . The pharmaceutical composition of claim 49 , wherein the IGF-1-encoding DNA construct is IGF-1X10.
51 - 62 . (canceled)
63 . A kit for treating neuropathy, comprising:
a first pharmaceutical composition comprising an IGF-1-encoding DNA construct comprising a polynucleotide of SEQ ID NO: 10, and a first pharmaceutically acceptable excipient; and
a second pharmaceutical composition comprising an HGF-encoding DNA construct comprising a polynucleotide of SEQ ID NO: 13, and a second pharmaceutically acceptable excipient.
64 - 121 . (canceled)